Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE.

Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x.

2.

Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.

Abd Elmoneim A, Gore L, Ricklis RM, Boklan J, Cooper T, Narendran A, Rolla K, Scott T, Arceci RJ.

Pediatr Blood Cancer. 2012 Dec 15;59(7):1252-8. doi: 10.1002/pbc.24264.

PMID:
22887831
3.

A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.

Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL.

Leukemia. 2009 Dec;23(12):2259-64. doi: 10.1038/leu.2009.185.

PMID:
19741725
4.

Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.

Steinherz PG, Shukla N, Kobos R, Steinherz L.

Pediatr Blood Cancer. 2010 May;54(5):687-93. doi: 10.1002/pbc.22321.

PMID:
20205253
5.

Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.

Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, Ziino O, Parasole R, Luciani M, Lo Nigro L, De Rossi G, Varotto S, Bertorello N, Petruzziello F, Calvillo M, Micalizzi C.

Leuk Lymphoma. 2012 Sep;53(9):1693-8. doi: 10.3109/10428194.2012.663915.

PMID:
22303898
6.

Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.

Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, Pession A, Giraldi E, Parasole R, Barberi W, Zecca M.

Br J Haematol. 2009 Nov;147(3):371-8. doi: 10.1111/j.1365-2141.2009.07882.x.

PMID:
19747360
7.

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.

Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, Kadota R, Cooper T, Shen V, Dahl G, Thottassery JV, Jeha S, Maloney K, Paul JA, Barry E, Carroll WL, Gaynon PS.

Blood. 2011 Dec 1;118(23):6043-9. doi: 10.1182/blood-2011-08-374710.

8.

A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).

Nelken B, Cave H, Leverger G, Galambrun C, Plat G, Schmitt C, Thomas C, Vérité C, Brethon B, Gandemer V, Bertrand Y, Baruchel A, Rohrlich P.

Pediatr Blood Cancer. 2016 Feb;63(2):270-5. doi: 10.1002/pbc.25751.

PMID:
26376115
9.

Clofarabine/cyclophosphamide for debulking before stem cell transplantation.

Rabitsch W, Böhm A, Bojic M, Schellongowski P, Wöhrer S, Sliwa T, Keil F, Worel N, Greinix H, Hauswirth A, Kalhs P, Jaeger U, Valent P, Sperr WR.

Eur J Clin Invest. 2014 Aug;44(8):775-83. doi: 10.1111/eci.12294.

PMID:
24942362
10.

Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):231-8. doi: 10.1016/j.clml.2013.12.001.

11.

A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.

Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS.

Biol Blood Marrow Transplant. 2011 Jul;17(7):987-94. doi: 10.1016/j.bbmt.2010.10.016.

12.

Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.

Suzuki T, Yamauchi T, Ando K, Nagai T, Kakihana K, Miyata Y, Uchida T, Tabata Y, Ogura M.

Jpn J Clin Oncol. 2013 Dec;43(12):1177-83. doi: 10.1093/jjco/hyt155.

PMID:
24130086
13.

Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.

Barba P, Sampol A, Calbacho M, Gonzalez J, Serrano J, Martínez-Sánchez P, Fernández P, García-Boyero R, Bueno J, Ribera JM.

Am J Hematol. 2012 Jun;87(6):631-4. doi: 10.1002/ajh.23167.

14.

Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.

Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A.

Am J Hematol. 2012 Dec;87(12):1047-51. doi: 10.1002/ajh.23308.

15.

Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.

Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG.

Pediatr Blood Cancer. 2014 Mar;61(3):431-5. doi: 10.1002/pbc.24789.

PMID:
24115731
16.

Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.

Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S.

Am J Hematol. 2013 Nov;88(11):961-6. doi: 10.1002/ajh.23544.

17.

The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.

McGregor BA, Brown AW, Osswald MB, Savona MR.

Am J Hematol. 2009 Apr;84(4):228-30. doi: 10.1002/ajh.21365. Review.

18.

Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.

Loeffler C, Kapp M, Grigoleit GU, Mielke S, Loeffler J, Heuschmann PU, Malzahn U, Hupp E, Einsele H, Stuhler G.

Leuk Lymphoma. 2015;56(12):3365-9. doi: 10.3109/10428194.2015.1020059.

PMID:
26014275
19.

Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.

Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M, Stuart R, Ganguly S, Avigan D, Craig M, Collins R, Maris M, Kovacsovics T, Goldberg S, Seiter K, Hari P, Greiner J, Vey N, Recher C, Ravandi F, Wang ES, Vasconcelles M, Huebner D, Kantarjian HM.

J Clin Oncol. 2012 Jul 10;30(20):2492-9. doi: 10.1200/JCO.2011.37.9743.

20.

Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.

Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE.

Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900. doi: 10.1016/j.bbmt.2010.09.022.

Supplemental Content

Support Center